Study Summary
This trial tests a new drug to treat active Systemic Lupus Erythematosus (SLE) to see if it's safe and effective. #SLE #clinicaltrial
- Lupus
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 16 Secondary · Reporting Duration: Up to 156 weeks
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Arm 1: Deucravacitinib
1 of 2
Arm 2: Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
490 Total Participants · 2 Treatment Groups
Primary Treatment: Arm 1: Deucravacitinib · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 75 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Am I eligible to enroll in this research study?
"Up to 490 patients with systemic lupus erythematosus between the ages of 18 and 75 will be admitted into this trial. Eligibility criteria include: a positive ANA reading ≥ 1:80, a SLEDAI-2K score ≥ 6 points, clinical SLEDAI 2K score ≥ 4 points with joint involvement and/or rash, a diagnosis of SLE at least 24 weeks before screening, meeting the 2019 EULAR/ACR classification criteria for SLE, and being on one or more background therapies (immunosuppressant and/or antimalarial) for 12 weeks prior" - Anonymous Online Contributor
Are there any more positions available for test subjects?
"According to the information readily available on clinicaltrials.gov, this trial is no longer looking for patients as of their last update on November 8th, 2022. This study was initially posted on 21/11/2022. Right now, there are 128 other trials that are actively recruiting patients." - Anonymous Online Contributor
Does this research include elderly participants?
"The age requirement for this clinical trial is that patients must be over 18 but under 75 years old." - Anonymous Online Contributor
What is the status of Deucravacitinib's FDA approval?
"We believe that arm 1 of the deucravacitinib clinical trial is safe, as it has received a score of 3. This is due to there being data supporting efficacy and safety from multiple rounds of testing." - Anonymous Online Contributor
Is this trial taking place in more than one urban location?
"With 21 sites available, patients have plenty of options for participating in this study. Some notable locations include the Arthritis & Rheumatology Research Institute in Allen, Yale University School of Medicine in New Haven, and the University of Florida College of Medicine in Gainesville." - Anonymous Online Contributor